Impact of interstitial lung disease on clinical remission and unfavourable events of rheumatoid arthritis: results from the Institute of Rheumatology, Rheumatoid Arthritis (IORRA) cohort
Main finding · DAS28 remission achieved at least once within 5 yearsResult — go to the resultAHR for achieving DAS28 remission (time to remission) 0.71 95% CI 0.58–0.89Authors' conclusion
Concomitant ILD was a significant factor associated with failure to achieve clinical remission and the occurrence of the unfavourable clinical events in patients with RA.
Study context
- Population
- Patients with RA in the IORRA cohort (2011–2012) not in disease activity score (DAS28) remission at baseline and with chest CT images
- Participants
- 287 vs 1,235
- Exposure
- RA with interstitial lung disease (ILD) vs RA without ILD
- ILDn = 287
- non-ILDn = 1,235reference
- Outcome
- Time to achieving DAS28 remission
- Follow-up
- 5 years
Methodological detailstime-dependent Cox regression
- Time-dependent Cox regression
Main finding
As reported in the abstract
DAS28 remission achieved at least once within 5 years
AHR for achieving DAS28 remission (time to remission)
0.71
95% CI 0.58–0.89
By group
ILDvs Non-ILD
aHR for achieving DAS28 remission (time to remission) 0.71 (95% CI 0.58–0.89)
Observational data: associations, not effects.
Further findings
| Outcome | aHR (95% CI) | |
|---|---|---|
| Death · 5 years | 3.24 (2.08–5.03) | |
| Hospitalized infection · 5 years | 2.60 (1.77–3.83) | |
| MACE · 5 years | 3.40 (1.76–6.58) | |
| Lung cancer · 5 years | 16.0 (3.22–79.2) | |
| Malignant lymphoma · 5 years | 2.27 (0.59–8.81) | |
| 0.050.21520Adjusted hazard ratio (log scale) |
Original publication
Impact of interstitial lung disease on clinical remission and unfavourable events of rheumatoid arthritis: results from the IORRA cohort. Rheumatology (Oxford). Published 28 June 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →